First, I owe everyone an apology for this week. I’ve been sick in bed for most of it and, as usual, I’m running behind schedule.
Thank you for your patience and for the many thoughtful questions and research requests you’ve sent our way. We have a substantial volume of responses and new research material coming your way this weekend.
One of the questions I receive most frequently goes something like this:
“I’m interested in fenbendazole, so why do so many of your articles focus on mebendazole?”
It’s an excellent question, and I want to explain why we devote so much attention to both drugs.
Our Approach to Medical Research
Our work is built around published medical research, scientific papers, and clinical findings. Occasionally, we also examine preprints—research papers that have not yet undergone peer review. We review the available evidence, summarize the findings, and present the information in a way that everyday readers can understand.
Our goal is simple: Make medical research more accessible to people who are searching for answers.
Imagine you’ve recently heard the devastating words, “You have cancer.”
Alongside your doctor’s recommendations, you begin exploring complementary treatments and emerging research. Eventually, you turn to Google and search for “fenbendazole for cancer.”
What you discover may be frustrating.
You might encounter statements such as:
“There is no established evidence that fenbendazole treats cancer in humans.”
“There are no completed human clinical trials demonstrating its effectiveness against cancer.”
“Fenbendazole is a veterinary dewormer, not an approved human cancer treatment.”
While these statements reflect important limitations in the clinical evidence, they don’t tell the entire research story.
There is a substantial body of early-stage, preclinical research involving fenbendazole, including laboratory experiments (in vitro) and animal studies (in vivo). Researchers have investigated its effects on cancer cells, tumor growth, and several biological mechanisms associated with cancer.
However, these findings are scattered across scientific journals and medical research databases. Much of this material is difficult for the average person to locate, interpret, or evaluate.
A simple Google search may never lead you to the studies you actually want to read.
That’s one of the gaps we’re trying to fill.
We search the medical literature, examine the research, and bring those findings together in one place so readers can better understand both the potential and the limitations of these drugs.
Why So Much Research Focuses on Mebendazole
Here’s an important distinction that helps explain the difference in the available scientific literature.
Mebendazole is an established medication for human use. Fenbendazole is primarily a veterinary medication.
As a result, mebendazole has a longer history of human medical use, and researchers have been able to build on existing knowledge about its safety, pharmacology, and clinical applications.
Fenbendazole, on the other hand, has not been approved for human use by the FDA. Although it has attracted considerable interest in cancer research, its clinical development has been much more limited.
Consequently, when we examine repurposed antiparasitic drugs as potential cancer treatments, a significant portion of the relevant human clinical research involves mebendazole rather than fenbendazole.
This doesn’t mean the two drugs are identical or that results from one can automatically be applied to the other.
But they are closely related, which makes understanding both drugs worthwhile.
Fenbendazole and Mebendazole: Understanding the Drug Family
Fenbendazole and mebendazole belong to a class of antiparasitic drugs known as benzimidazoles. More specifically, both are classified as benzimidazole carbamates.
Other medications in the broader benzimidazole family include:
Albendazole
Flubendazole
Oxfendazole
Oxibendazole
Thiabendazole (an older, non-carbamate benzimidazole)
Mebendazole and albendazole are widely recognized medications used in human medicine.
Fenbendazole is primarily used in veterinary medicine to treat parasitic infections in animals, including dogs, cats, horses, and livestock.
How Do These Drugs Work?
These medications share an important mechanism of action against parasites.
They bind to a protein called β-tubulin, interfering with the formation of microtubules—essential structures involved in cell division, intracellular transport, and other cellular functions.
In susceptible parasites, this disruption interferes with glucose uptake and other vital processes, eventually leading to the parasite’s death.
Benzimidazole anthelmintics generally bind more strongly to susceptible parasite tubulin than to mammalian tubulin, contributing to their therapeutic selectivity when used appropriately. They don’t hurt the surrounding tissue or organs.
Here’s where the cancer research becomes especially interesting.
Microtubules are also essential to the growth and division of cancer cells.
Researchers have investigated whether drugs such as fenbendazole and mebendazole can interfere with these processes in malignant cells.
Several laboratory studies have reported effects on cancer-cell proliferation, cell division, and survival.
However, an important distinction must be made: Activity against cancer cells in laboratory experiments does not establish that these drugs can safely and effectively treat cancer in humans or selectively destroy tumors without harming healthy tissue.
That question requires carefully designed clinical studies.
Why Is Fenbendazole So Popular?
Fenbendazole has attracted considerable attention among people researching alternative and complementary approaches to cancer.
Two major reasons are its low cost and widespread availability.
Its popularity has also been fueled by numerous personal accounts, testimonials, social media discussions, and stories from people who believe fenbendazole helped them during their cancer treatment.
These stories are worth understanding.
Many individuals reporting favorable outcomes have also undergone surgery, chemotherapy, radiation, immunotherapy, or other conventional treatments. Without properly controlled studies, it can be extremely difficult to determine which treatment contributed to their results.
Meanwhile, mebendazole has accumulated a larger body of published research involving human use, including limited clinical investigations of its potential role in cancer treatment.
This difference in the available evidence explains much of the disparity between what readers find about fenbendazole and what they find about mebendazole.
Our Two End-of-Year Research Reports
To help readers understand the available evidence, I’ve prepared two comprehensive reports:
1. Fenbendazole Cancer Research: End-of-Year Summary
2. Mebendazole Cancer Research: End-of-Year Summary
Both reports examine the medical research we were able to locate, including laboratory studies, animal experiments, published reviews, and relevant human clinical research.
We look at what researchers tested, what they observed, and what their findings may mean for future investigation.
We also distinguish between promising early results and findings that have actually been demonstrated in human patients.
That distinction is critically important.
What Do Human Clinical Trials Tell Us?
One of the most significant differences between these drugs is the availability of human clinical evidence.
Fenbendazole has not been established as a safe or effective cancer treatment in humans, and published controlled human cancer trials demonstrating its efficacy remain lacking.
Much of the available research is preclinical, involving cancer cells grown in laboratories or experimental animal models.
Fenbendazole is also an older, off-patent veterinary medication. Its limited commercial incentives may be one factor affecting interest in further development, although funding decisions, safety considerations, and scientific priorities are also important.
Mebendazole presents a somewhat different picture.
Because it is already an approved human antiparasitic medication, researchers have been able to investigate its potential for repurposing in cancer treatment.
A small number of human clinical studies have explored its safety, tolerability, and possible anticancer applications.
Although the available human evidence remains limited and has not established mebendazole as an effective cancer treatment, the research has generated findings worthy of further investigation.
Encouraging Findings From Combination Treatments
Some particularly interesting preclinical studies have investigated mebendazole alongside established cancer therapies.
For example, researchers have examined combinations involving docetaxel, a chemotherapy medication used to treat several cancers.
In experimental models, certain combinations have demonstrated enhanced antitumor activity compared with individual treatments.
Other studies have explored whether mebendazole could increase the effectiveness of conventional therapies or interfere with mechanisms that contribute to treatment resistance.
These findings are encouraging from a research perspective.
What About Chemotherapy, Radiation, and Other Drug Combinations?
A 2019 scientific review discussed several potential anticancer mechanisms of mebendazole, including its possible interaction with radiation therapy and established cancer medications.
The review examined research suggesting that mebendazole may enhance the activity of certain treatments in experimental settings.
Among the chemotherapy medications investigated were:
Cisplatin
Paclitaxel
Doxorubicin
Temozolomide
Researchers have also explored combinations involving targeted therapies, including MEK inhibitors such as trametinib in melanoma research, as well as EGFR-targeted treatments.
Additional preclinical work has investigated combinations involving the anti-inflammatory medication celecoxib, particularly in experimental models related to colorectal cancer.
Some research has also suggested that mebendazole may influence immune mechanisms involved in the body’s response to tumors.
These findings help explain why scientists remain interested in the drug.
But again, promising laboratory results and experimental drug combinations are not proof of clinical effectiveness in cancer patients.
They provide a scientific foundation for further investigation.
Why Our Reports Focus on Medical Papers, Not Internet Testimonials
There’s certainly no shortage of information online about fenbendazole and cancer.
You can find interviews, podcasts, YouTube videos, personal success stories, and discussions across countless websites and social media platforms.
Many readers are familiar with Mel Gibson’s appearance on Joe Rogan’s podcast, the numerous online cancer-cure testimonials, and Joe Tippens’ widely discussed experience with fenbendazole.
We’ve examined these stories before, and they are part of the broader public conversation.
However, these two end-of-year reports have a different purpose.
They focus primarily on published scientific research, medical papers, experimental findings, and clinical evidence.
You won’t find extensive discussions of celebrity interviews, dozens of YouTube cancer-cure claims, or lengthy accounts of individual testimonials.
Instead, you’ll find research.
What did scientists investigate? What methods did they use? What were the results? How reliable are those findings? And, perhaps most importantly, what questions remain unanswered?
That’s the information we want readers to have.
What Does the Lack of Human Research Really Mean?
Despite the tremendous amount of online discussion surrounding fenbendazole, it is not an established or approved treatment for human cancer.
The scientific literature includes interesting preclinical findings, but the human clinical evidence needed to demonstrate safety and effectiveness is still missing.
That does not automatically mean fenbendazole has no anticancer potential.
It means that its effectiveness against human cancer has not been adequately established through clinical research.
Likewise, mebendazole’s history of safe use for approved antiparasitic indications does not establish that it is safe or effective when used in different doses, combinations, or treatment schedules for cancer.
There are still important questions about absorption, dosing, toxicity, drug interactions, and whether the concentrations producing anticancer effects in laboratory experiments can be achieved safely in humans.
For these reasons, the limited evidence should not be interpreted as a recommendation to start, continue, or discontinue either drug for cancer treatment without medical guidance.
Anyone considering these medications should discuss them openly with their oncologist, particularly because potential side effects and interactions may affect conventional cancer treatment.
Our Goal: Better Information, Better Questions, and More Research
I believe readers deserve access to the scientific evidence, including research that may not be widely discussed outside medical journals.
Our purpose is not to tell anyone which treatment to take or to promise results that science has not yet demonstrated.
Our purpose is to find the research, examine the evidence, explain the findings, and help you make more informed decisions alongside your medical team.
There is still much to learn about fenbendazole, mebendazole, and the broader family of repurposed antiparasitic medications.
Some findings are encouraging. Others reveal significant limitations. Both deserve attention.
I hope these two reports help you better understand why we research both drugs, what the scientific literature actually tells us, and where future studies may lead.
Thank you again for your patience, your questions, and your continued support.
We have a busy weekend ahead, and I look forward to sharing much more research with you.
As always, please leave your questions and comments. Your requests help guide the research we do next.
Disclaimer: This article is for informational and educational purposes only. We are not medical professionals and do not provide medical advice. Neither fenbendazole nor mebendazole is approved by the FDA for cancer treatment. Always consult your physician or oncologist before considering changes to your treatment plan.